<DOC>
	<DOC>NCT01187628</DOC>
	<brief_summary>The objective of this study is to investigate the safety and the effect on reduction of serum phosphate of long-term administration of lanthanum carbonate (BAY77-1931) 750 to 2250 mg in patients with hyperphosphatemia who completed the 8 week double-blind treatment period of Study 14817 and are judged to be eligible for the long-term extension study.</brief_summary>
	<brief_title>Long-term Study in Chronic Kidney Disease (Extension From Study 14817)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients who have completed the 8week doubleblind treatment period of Study 14817 and are judged to be eligible for the longterm extension study by the investigator (including those who plan to be on dialysis during the longterm extension study). Patients with any other conditions that the investigator defines as not appropriate to be enrolled in the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Long-term study in Chronic Kidney Disease</keyword>
	<keyword>Lanthanum Carbonate</keyword>
</DOC>